BRIEF—Eisai boosts evidence for Lenvima in liver cancer

An analysis of the Phase III REFLECT study, presented by Eisai at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), has confirmed findings from the primary analysis.

The trial compared Lenvima (lenvatinib mesylate), which is marketed as Kisplyx in the EU, with Nexavar (sorafenib) as a first-line treatment for liver cancer.

The data relate to the secondary endpoints of progression-free survival (PFS), time to progression (TTP), and objective response rate (ORR), confirming extensions in PFS and TTP and an increase in ORR compared to Nexavar.

Safety data were consistent with the known safety profile of the therapy.

Eisai submitted applications to extend the label for Lenvima to include liver cancer in Japan, the USA and Europe in mid-2017.